Trials / Sponsors / Calcilytix Therapeutics, Inc., a BridgeBio company
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry · 4 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalc Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2 / Phase 3 | 2026-01-30 |
| Active Not Recruiting | Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | 2023-01-06 |
| Active Not Recruiting | ADH1 and ADH2 Disease Monitoring Study (DMS) Autosomal Dominant Hypocalcemia | — | 2022-01-20 |
| Completed | Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Typ Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Phase 2 | 2020-09-20 |